COVID‐19 vaccine adverse events: Evaluating the pathophysiology with an emphasis on sulfur metabolism and endotheliopathy

Documenti analoghi

• Nationwide estimates of SARS‐CoV‐2 infection fatality rates and numbers needed to vaccinate for COVID‐19 vaccines in 2024 in Austria
  di: Uwe Riedmann, et al.
  Pubblicazione: (2025)
• Batch‐dependent safety of COVID‐19 vaccines in the Czech Republic and comparison with data from Denmark
  di: Tomáš Fürst, et al.
  Pubblicazione: (2024)
• Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID‐19 vaccine
  di: Luis Jara‐Palomares, et al.
  Pubblicazione: (2024)
• Primary mitochondrial diseases: The intertwined pathophysiology of bioenergetic dysregulation, oxidative stress and neuroinflammation
  di: Kevin Aguilar, et al.
  Pubblicazione: (2024)
• Neutrophil degranulation, endothelial and metabolic dysfunction in unvaccinated long COVID patients
  di: Agostino Di Ciaula, et al.
  Pubblicazione: (2024)